Advances in protein–protein interaction analysis and modulation edition:2 location:Hyères date:9-12 September 2014
Candida albicans is an opportunistic pathogen for humans. At the moment is the fourth most common nosocomial infection. It has a mortality rate of 40%. C. albicans is well adapted to the survival in the human body. It can form biofilms on medic devices, organs and the skin. Besides forming biofilms C. albicans can tolerate high stress environments in the body. It can, e.g.., survive in phagocytes by adapting its metabolism from using glucose to lactate as a carbon source.
There are only a few anti mycota avaible and resistance against almost all of them has been described. It is therefore important to find novel anti mycota. In order to find novel, specific, anti mycota we will investigate novel protein-protein interactions using an adapted yeast two hybrid system, bimolecular fluorescence complementation (BiFC) and a luciferase complementation assay (LCA). Due to the fact that C. albicans has a different codon usage (CUG; translated as serine rather than leucine) we developed a Candida two hybrid (C2H) screening. Because of the nature of this system, forced movement to the nucleus, it is hard to study protein interactions that are important for the cell wall homeostasis. To overcome this we will also apply the BiFC and LCA. By using multiple systems we can overcome the boundaries of each specific system and identify potential novel drugs targets to overcome C. albicans infections.